Discussion on effect of combined use of butylphthalide and edaravone in patients with acute cerebral infarction
Objective To explore the clinical effect of combined use of butylphthalide and edaravone in the treatment of patients with acute cerebral infarction.Methods 76 patients with acute cerebral infarction were randomly divided into an observation group and a control group according to random numerical table.The control group was treated with butylphthalide,while the observation group was treated with butylphthalide and edaravone.The treatment effect,neurological function defect,self-care ability,serum inflammatory mediator levels,quality of life,and improvement of negative emotions were compared between the two groups.Results The total effective rate of 94.74%in the observation group was significantly higher than that of 78.95%in the control group,and the difference was statistically significant(P<0.05).After treatment,the National Institutes of Health Stroke Scale(NIHSS)score in both groups was lower than that before treatment in this group,and the modified Barthel index(BI)score was higher than that before treatment in this group;NIHSS score of(12.30±1.23)points in the observation group was lower than that of(24.61±1.80)points in the control group;BI score of(81.45±8.27)points in the observation group was higher than that of(74.39±7.46)points in the control group;the differences were statistically significant(P<0.05).After treatment,the scores of social functioning,physical functioning,role-emotional,role-physical,mental health,vitality,overall health,and bodily pain of patients in the observation group were(86.22±3.34),(86.19±4.55),(89.33±3.23),(88.11±5.21),(90.64±1.87),(83.19±3.23),(87.43±3.22),and(83.15±2.98)points,which were significantly higher than those of(83.11±2.42),(80.98±5.21),(83.21±4.01),(83.33±4.43),(84.19±2.76),(76.34±2.58),(82.12±2.67),and(77.19±3.04)points in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of interleukin-6(IL-6),interleukin-8(IL-8)and tumor necrosis factor-α(TNF-α)in both groups were lower than those before treatment in this group;the observation group had IL-6 of(3.86±1.03)ng/L,IL-8 of(0.46±0.05)ng/ml and TNF-α of(138.62±26.31)pg/ml,which were lower than those of(4.69±1.05)ng/L,(0.51±0.08)ng/ml and(351.62±29.62)pg/ml in the control group;the difference was statistically significant(P<0.05).After treatment,the scores of self-rating anxiety scale(SAS)and self-rating depression scale(SDS)in both groups were lower than those before treatment in this group;SAS score of(50.38±2.24)points and SDS score of(52.01±2.24)points in the observation group were lower than those of(55.86±3.03)and(56.69±3.02)points in the control group;the difference was statistically significant(P<0.05).Conclusion The combined use of butylphthalide and edaravone in the treatment of patients with acute cerebral infarction can play a prominent role.It can not only improve the patients'neurological function defect and self-care ability,but also decrease the level of serum inflammatory factors and improve the patients'quality of life,which is worthy of promotion and application.
NETL
NSTL
万方数据
维普
